You Lü
Impact in
- Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Lung Cancer Treatments and Mutations 68
- Lung Cancer Diagnosis and Treatment 28
- Oncology 61
- Cancer Immunotherapy and Biomarkers 32
- Lung Cancer Research Studies 11
- Co-authors
- Guangping Gao (7 shared papers)Roberto Calcedo (5 shared papers)James M. Wilson (5 shared papers)Jianxin Xue (47 shared papers)Luk H. Vandenberghe (2 shared papers)Mauricio R. Alvira (2 shared papers)Xiangyang Zhou (1 shared paper)Lin Zhou (47 shared papers)
- Journals
- International Journal of Radiation Oncology*Biology*Physics (22 papers)Journal of Thoracic Oncology (14 papers)Annals of Oncology (14 papers)Lung Cancer (10 papers)Journal of Cancer Research and Clinical Oncology (5 papers)
- Partner nations
- ChinaUnited StatesSouth Korea
In The Last Decade
You Lü
258 papers receiving 9.6k citations
You Lü's Hit Papers
Peers
Comparison fields: 5 of 129
- Pulmonary and Respiratory Medicine 3k
- Oncology 2k
- Genetics 1.3k
- Cancer Research 555
- Immunology 514
Countries citing papers authored by You Lü
This map shows the geographic impact of You Lü's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by You Lü with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites You Lü more than expected).
Fields of papers citing papers by You Lü
This network shows the impact of papers produced by You Lü. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by You Lü. The network helps show where You Lü may publish in the future.
Co-authors
The 25 scholars most cited alongside You Lü, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 267 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues Hit paper breakdown → | 2004 | 894 |
| 2 | Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer Hit paper breakdown → | 2020 | 448 |
| 3 | Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial Hit paper breakdown → | 2015 | 354 |
| 4 | BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer Hit paper breakdown → | 2015 | 311 |
| 5 | 2020 | 305 | |
| 6 | 2019 | 302 | |
| 7 | 2003 | 277 | |
| 8 | 2000 | 214 | |
| 9 | 2018 | 210 | |
| 10 | AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations Hit paper breakdown → | 2022 | 210 |
| 11 | 2013 | 195 | |
| 12 | Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer Hit paper breakdown → | 2022 | 185 |
| 13 | 2017 | 149 | |
| 14 | 2018 | 149 | |
| 15 | 2005 | 147 | |
| 16 | 2014 | 130 | |
| 17 | 2007 | 128 | |
| 18 | 2019 | 122 | |
| 19 | 2018 | 119 | |
| 20 | 2020 | 117 |
About You Lü
You Lü is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Radiation, Cancer Research and Surgery, having authored 267 papers that have together received 9.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (68 papers), Cancer Immunotherapy and Biomarkers (32 papers), Lung Cancer Diagnosis and Treatment (28 papers), Esophageal Cancer Research and Treatment (19 papers), Angiogenesis and VEGF in Cancer (12 papers), Lung Cancer Research Studies (11 papers), Immunotherapy and Immune Responses (11 papers) and Advanced Radiotherapy Techniques (10 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (3k citations), Oncology (2k citations), Genetics (1.3k citations), Cancer Research (555 citations) and Immunology (514 citations). You Lü has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Guangping Gao, Roberto Calcedo, James M. Wilson, Jianxin Xue, Luk H. Vandenberghe, Mauricio R. Alvira, Xiangyang Zhou, Lin Zhou, Yi-Long Wu and Lei Deng. Their work appears in journals such as International Journal of Radiation Oncology*Biology*Physics, Journal of Thoracic Oncology, Annals of Oncology, Lung Cancer and Journal of Cancer Research and Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.